Investig Clin Urol.  2017 Jun;58(Suppl 1):S38-S45. 10.4111/icu.2017.58.S1.S38.

Endoscopic injection therapy

• Kim SW
• Lee YS
• Han SW

• KMID: 2379894
• DOI: http://doi.org/10.4111/icu.2017.58.S1.S38

Abstract

Since the U.S. Food and Drug Administration approved dextranomer/hyaluronic acid copolymer (Deflux) for the treatment of vesicoureteral reflux, endoscopic injection therapy using Deflux has become a popular alternative to open surgery and continuous antibiotic prophylaxis. Endoscopic correction with Deflux is minimally invasive, well tolerated, and provides cure rates approaching those of open surgery (i.e., approximately 80% in several studies). However, in recent years a less stringent approach to evaluating urinary tract infections (UTIs) and concerns about long-term efficacy and complications associated with endoscopic injection have limited the use of this therapy. In addition, there is little evidence supporting the efficacy of endoscopic injection therapy in preventing UTIs and vesicoureteral reflux-related renal scarring. In this report, we reviewed the current literature regarding endoscopic injection therapy and provided an updated overview of this topic.

Keyword

Endoscopy; Injections; Vesicoureteral reflux

MeSH Terms

Antibiotic Prophylaxis
Cicatrix
Endoscopy
United States Food and Drug Administration
Urinary Tract Infections
Vesico-Ureteral Reflux

Reference

1. Peters CA, Skoog SJ, Arant BS Jr, Copp HL, Elder JS, Hudson RG, et al. Summary of the AUA guideline on management of primary vesicoureteral reflux in children. J Urol. 2010; 184:1134–1144.

2. Matouschek E. New concept for the treatment of vesico-ureteral reflux. Endoscopic application of teflon. Arch Esp Urol. 1981; 34:385–388.

3. O'Donnell B, Puri P. Treatment of vesicoureteric reflux by endoscopic injection of Teflon. Br Med J (Clin Res Ed). 1984; 289:7–9.

4. Chertin B, Colhoun E, Velayudham M, Puri P. Endoscopic treatment of vesicoureteral reflux: 11 to 17 years of followup. J Urol. 2002; 167:1443–1445.

5. Yücel S, Tarcan T, Simşek F. Durability of a single successful endoscopic polytetrafluoroethylene injection for primary vesicoureteral reflux: 14-year followup results. J Urol. 2007; 178:265–268.

6. Puri P. Ten year experience with subureteric Teflon (polytetrafluoroethylene) injection (STING) in the treatment of vesicoureteric reflux. Br J Urol. 1995; 75:126–131.

7. Vandenbossche M, Delhove O, Dumortier P, Deneft F, Schulman CC. Endoscopic treatment of reflux: experimental study and review of Teflon and collagen. Eur Urol. 1993; 23:386–393.

8. Aaronson IA, Rames RA, Greene WB, Walsh LG, Hasal UA, Garen PD. Endoscopic treatment of reflux: migration of Teflon to the lungs and brain. Eur Urol. 1993; 23:394–399.

9. Solomon LZ, Birch BR, Cooper AJ, Davies CL, Holmes SA. Nonhomologous bioinjectable materials in urology: ‘size matters’? BJU Int. 2000; 85:641–645.

10. Chertin B, Puri P. Endoscopic management of vesicoureteral reflux: does it stand the test of time? Eur Urol. 2002; 42:598–606.

11. Smith DP, Kaplan WE, Oyasu R. Evaluation of polydimethylsiloxane as an alternative in the endoscopic treatment of vesicoureteral reflux. J Urol. 1994; 152:1221–1224.

12. Henly DR, Barrett DM, Weiland TL, O'Connor MK, Malizia AA, Wein AJ. Particulate silicone for use in periurethral injections: local tissue effects and search for migration. J Urol. 1995; 153:2039–2043.

13. Lendvay TS, Sorensen M, Cowan CA, Joyner BD, Mitchell MM, Grady RW. The evolution of vesicoureteral reflux management in the era of dextranomer/hyaluronic acid copolymer: a pediatric health information system database study. J Urol. 2006; 176(4 Pt 2):1864–1867.

14. Nelson CP, Copp HL, Lai J, Saigal CS. Urologic Diseases in America Project. Is availability of endoscopy changing initial management of vesicoureteral reflux? J Urol. 2009; 182:1152–1157.

15. Routh JC, Inman BA, Reinberg Y. Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics. 2010; 125:1010–1019.

16. Läckgren G, Wåhlin N, Sköldenberg E, Stenberg A. Long-term followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol. 2001; 166:1887–1892.

17. Chertin B, Natsheh A, Fridmans A, Shenfeld OZ, Farkas A. Renal scarring and urinary tract infection after successful endoscopic correction of vesicoureteral reflux. J Urol. 2009; 182:4 Suppl. 1703–1706.

18. Kirsch AJ, Perez-Brayfield MR, Scherz HC. Minimally invasive treatment of vesicoureteral reflux with endoscopic injection of dextranomer/hyaluronic acid copolymer: the Children's Hospitals of Atlanta experience. J Urol. 2003; 170:211–215.

19. Holmdahl G, Brandström P, Läckgren G, Sillén U, Stokland E, Jodal U, et al. The Swedish reflux trial in children: II. Vesicoureteral reflux outcome. J Urol. 2010; 184:280–285.

20. Chertin B, Kocherov S. Long-term results of endoscopic treatment of vesicoureteric reflux with different tissue-augmenting substances. J Pediatr Urol. 2010; 6:251–256.

21. Lee EK, Gatti JM, Demarco RT, Murphy JP. Long-term follow-up of dextranomer/hyaluronic acid injection for vesicoureteral reflux: late failure warrants continued followup. J Urol. 2009; 181:1869–1874.

22. Ormaechea M, Ruiz E, Denes E, Gimenez F, Dénes FT, Moldes J, et al. New tissue bulking agent (polyacrylate polyalcohol) for treating vesicoureteral reflux: preliminary results in children. J Urol. 2010; 183:714–717.

23. Kocherov S, Ulman I, Nikolaev S, Corbetta JP, Rudin Y, Slavkovic A, et al. Multicenter survey of endoscopic treatment of vesicoureteral reflux using polyacrylate-polyalcohol bulking copolymer (Vantris). Urology. 2014; 84:689–693.

24. Karakus SC, User İR, Kılıc BD, Akçaer V, Ceylan H, Ozokutan BH. The comparison of dextranomer/hyaluronic acid and polyacrylate-polyalcohol copolymers in endoscopic treatment of vesicoureteral reflux. J Pediatr Surg. 2016; 51:1496–1500.

25. Kocaoglu C. Endoscopic treatment of grades IV and V vesicoureteral reflux with two bulking substances: dextranomer hyaluronic acid copolymer versus polyacrylate polyalcohol copolymer in children. J Pediatr Surg. 2016; 51:1711–1715.

26. Şencan A, Yıldırım H, Özkan KU, Uçan B, Karkıner A, Hoşgör M. Late ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer. Urology. 2014; 84:1188–1193.

27. Kajbafzadeh AM, Sabetkish S, Khorramirouz R, Sabetkish N. Comparison of histopathological characteristics of polyacrylate polyalcohol copolymer with dextranomer/hyaluronic acid after injection beneath the bladder mucosa layer: a rabbit model. Int Urol Nephrol. 2017; 49:747–752.

28. Capozza N, Caione P. Dextranomer/hyaluronic acid copolymer implantation for vesico-ureteral reflux: a randomized comparison with antibiotic prophylaxis. J Pediatr. 2002; 140:230–234.

29. Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz HC. The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol. 2004; 171(6 Pt 1):2413–2416.

30. Yap TL, Chen Y, Nah SA, Ong CC, Jacobsen A, Low Y. STING versus HIT technique of endoscopic treatment for vesicoureteral reflux: a systematic review and meta-analysis. J Pediatr Surg. 2016; 51:2015–2020.

31. Läckgren G, Kirsch AJ. Surgery Illustrated - Surgical Atlas Endoscopic treatment of vesicoureteral reflux. BJU Int. 2010; 105:1332–1347.

32. Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. Intermediate to long-term follow-up indicates low risk of recurrence after Double HIT endoscopic treatment for primary vesicoureteral reflux. J Pediatr Urol. 2012; 8:359–365.

33. Kaye JD, Srinivasan AK, Delaney C, Cerwinka WH, Elmore JM, Scherz HC, et al. Clinical and radiographic results of endoscopic injection for vesicoureteral reflux: defining measures of success. J Pediatr Urol. 2012; 8:297–303.

34. Kirsch AJ, Arlen AM, Lackgren G. Current trends in dextranomer hyaluronic acid copolymer (Deflux) injection technique for endoscopic treatment of vesicoureteral reflux. Urology. 2014; 84:462–468.

35. Gupta A, Snodgrass W. Intra-orifice versus hydrodistention implantation technique in dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol. 2008; 180:4 Suppl. 1589–1592.

36. Dave S, Lorenzo AJ, Khoury AE, Braga LH, Skeldon SJ, Suoub M, et al. Learning from the learning curve: factors associated with successful endoscopic correction of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer. J Urol. 2008; 180:4 Suppl. 1594–1599.

37. Yucel S, Gupta A, Snodgrass W. Multivariate analysis of factors predicting success with dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol. 2007; 177:1505–1509.

38. Kajbafzadeh AM, Tourchi A, Aryan Z. Factors that impact the outcome of endoscopic correction of vesicoureteral reflux: a multivariate analysis. Int Urol Nephrol. 2013; 45:1–9.

39. Hidas G, Soltani T, Watts B, Pribish M, Khoury AE. Is the appearance of the dextranomer/hyaluronic acid mound predictive of reflux resolution? J Urol. 2013; 189:1882–1885.

40. Dwyer ME, Husmann DA, Rathbun SR, Weight CJ, Kramer SA. Febrile urinary tract infections after ureteroneocystostomy and subureteral injection of dextranomer/hyaluronic acid for vesicoureteral reflux--do choice of procedure and success matter? J Urol. 2013; 189:275–282.

41. Sedberry-Ross S, Rice DC, Pohl HG, Belman AB, Majd M, Rushton HG. Febrile urinary tract infections in children with an early negative voiding cystourethrogram after treatment of vesicoureteral reflux with dextranomer/hyaluronic acid. J Urol. 2008; 180:4 Suppl. 1605–1609.

42. Kraft KH, Molitierno JA Jr, Dewhurst L, Geers C, Gunderson K, Scherz HC, et al. Is endoscopic injection therapy a reasonable treatment option for low-grade vesicoureteral reflux in association with overactive bladder? Urology. 2011; 78:675–678.

43. Läckgren G, Sköldenberg E, Stenberg A. Endoscopic treatment with stabilized nonanimal hyaluronic acid/dextranomer gel is effective in vesicoureteral reflux associated with bladder dysfunction. J Urol. 2007; 177:1124–1128.

44. Van Batavia JP, Nees SN, Fast AM, Combs AJ, Glassberg KI. Outcomes of vesicoureteral reflux in children with non-neurogenic lower urinary tract dysfunction treated with dextranomer/hyaluronic acid copolymer (Deflux). J Pediatr Urol. 2014; 10:482–487.

45. Perez-Brayfield M, Kirsch AJ, Hensle TW, Koyle MA, Furness P, Scherz HC. Endoscopic treatment with dextranomer/hyaluronic acid for complex cases of vesicoureteral reflux. J Urol. 2004; 172(4 Pt 2):1614–1616.

46. Cerwinka WH, Scherz HC, Kirsch AJ. Endoscopic treatment of vesicoureteral reflux associated with paraureteral diverticula in children. J Urol. 2007; 178(4 Pt 1):1469–1473.

47. Aydogdu O, Burgu B, Soygur T. Predictors of surgical outcome in children with vesicoureteral reflux associated with paraureteral diverticula. Urology. 2010; 76:209–214.

48. Elder JS, Diaz M, Caldamone AA, Cendron M, Greenfield S, Hurwitz R, et al. Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol. 2006; 175:716–722.

49. Lorenzo AJ, Pippi Salle JL, Barroso U, Cook A, Grober E, Wallis MC, et al. What are the most powerful determinants of endoscopic vesicoureteral reflux correction? Multivariate analysis of a single institution experience during 6 years. J Urol. 2006; 176(4 Pt 2):1851–1855.

50. Hunziker M, Mohanan N, Puri P. Dextranomer/hyaluronic acid endoscopic injection is effective in the treatment of intermediate and high grade vesicoureteral reflux in patients with complete duplex systems. J Urol. 2013; 189:1876–1881.

51. Molitierno JA Jr, Scherz HC, Kirsch AJ. Endoscopic injection of dextranomer hyaluronic acid copolymer for the treatment of vesicoureteral reflux in duplex ureters. J Pediatr Urol. 2008; 4:372–376.

52. Hensle TW, Reiley EA, Ritch C, Murphy A. The clinical utility and safety of the endoscopic treatment of vesicoureteral reflux in patients with duplex ureters. J Pediatr Urol. 2010; 6:15–22.

53. Chi A, Gupta A, Snodgrass W. Urinary tract infection following successful dextranomer/hyaluronic acid injection for vesicoureteral reflux. J Urol. 2008; 179:1966–1969.

54. Elder JS, Shah MB, Batiste LR, Eaddy M. Part 3: Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infections in patients with vesicoureteral reflux. Curr Med Res Opin. 2007; 23:Suppl 4. S15–S20.

55. Brandström P, Esbjörner E, Herthelius M, Swerkersson S, Jodal U, Hansson S. The Swedish reflux trial in children: III. Urinary tract infection pattern. J Urol. 2010; 184:286–291.

56. Brandström P, Nevéus T, Sixt R, Stokland E, Jodal U, Hansson S. The Swedish reflux trial in children: IV. Renal damage. J Urol. 2010; 184:292–297.

57. Nelson CP, Copp HL, Lai J, Saigal CS. Urologic Diseases in America Project. Is availability of endoscopy changing initial management of vesicoureteral reflux? J Urol. 2009; 182:1152–1157.

58. Stenberg A, Hensle TW, Läckgren G. Vesicoureteral reflux: a new treatment algorithm. Curr Urol Rep. 2002; 3:107–114.

59. Herbst KW, Corbett ST, Lendvay TS, Caldamone AA. Recent trends in the surgical management of primary vesicoureteral reflux in the era of dextranomer/hyaluronic acid. J Urol. 2014; 191:5 Suppl. 1628–1633.

60. Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011; 128:595–610.

61. Moorthy I, Easty M, McHugh K, Ridout D, Biassoni L, Gordon I. The presence of vesicoureteric reflux does not identify a population at risk for renal scarring following a first urinary tract infection. Arch Dis Child. 2005; 90:733–736.

62. Rubenwolf PC, Ebert AK, Ruemmele P, Rösch WH. Delayedonset ureteral obstruction after endoscopic dextranomer/hyaluronic acid copolymer (Deflux) injection for treatment of vesicoureteral reflux in children: a case series. Urology. 2013; 81:659–662.

63. Papagiannopoulos D, Rosoklija I, Cheng E, Yerkes E. Delayed obstruction with asymptomatic loss of renal function after dextranomer/hyaluronic acid copolymer (Deflux) injection for vesicoureteral reflux: a close look at a disturbing outcome. Urology. 2017; 101:63–66.

64. Zemple RP, Potretzke AM, Kryger JV. Delayed onset ureteral obstruction following Deflux® injection for vesicoureteral reflux. J Pediatr Urol. 2012; 8:e23–e26.

65. Vandersteen DR, Routh JC, Kirsch AJ, Scherz HC, Ritchey ML, Shapiro E, et al. Postoperative ureteral obstruction after subureteral injection of dextranomer/hyaluronic Acid copolymer. J Urol. 2006; 176(4 Pt 1):1593–1595.

66. Snodgrass WT. Obstruction of a dysmorphic ureter following dextranomer/hyaluronic acid copolymer. J Urol. 2004; 171:395–396.

67. Yankovic F, Swartz R, Cuckow P, Hiorns M, Marks SD, Cherian A, et al. Incidence of Deflux® calcification masquerading as distal ureteric calculi on ultrasound. J Pediatr Urol. 2013; 9(6 Pt A):820–824.

68. Romain J, Fourcade L, Centi J, Blanc P, Masselin MC, Lescure V, et al. Delayed-onset ureteral obstruction and calcification masquerading as renal colic following deflux injection. Urology. 2016; 94:218–220.

69. RIVUR Trial Investigators. Hoberman A, Greenfield SP, Mattoo TK, Keren R, Mathews R, et al. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014; 370:2367–2376.

70. Hunziker M, Mohanan N, D'Asta F, Puri P. Incidence of febrile urinary tract infections in children after successful endoscopic treatment of vesicoureteral reflux: a long-term follow-up. J Pediatr. 2012; 160:1015–1020.